Cullinan Therapeutics (CGEM) Research & Development (2021 - 2023)
Historic Research & Development for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to $34.8 million.
- Cullinan Therapeutics' Research & Development rose 6344.45% to $34.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $148.2 million, marking a year-over-year increase of 6113.02%. This contributed to the annual value of $142.9 million for FY2024, which is 354.56% down from last year.
- Cullinan Therapeutics' Research & Development amounted to $34.8 million in Q4 2023, which was up 6344.45% from $33.8 million recorded in Q3 2023.
- Cullinan Therapeutics' 5-year Research & Development high stood at $52.1 million for Q1 2023, and its period low was $11.8 million during Q2 2021.
- Its 3-year average for Research & Development is $24.8 million, with a median of $22.9 million in 2022.
- Within the past 5 years, the most significant YoY rise in Cullinan Therapeutics' Research & Development was 12424.01% (2022), while the steepest drop was 212.19% (2022).
- Quarter analysis of 3 years shows Cullinan Therapeutics' Research & Development stood at $20.9 million in 2021, then rose by 2.12% to $21.3 million in 2022, then skyrocketed by 63.44% to $34.8 million in 2023.
- Its Research & Development stands at $34.8 million for Q4 2023, versus $33.8 million for Q3 2023 and $27.4 million for Q2 2023.